Concord Biotech Limited (NSE:CONCORDBIO)

Market Cap	137.20B
Revenue (ttm)	11.25B
Net Income (ttm)	3.24B
Shares Out	104.62M
EPS (ttm)	30.89
PE Ratio	42.46
Forward PE	31.08
Dividend	10.70 (0.82%)
Ex-Dividend Date	Sep 3, 2025

Volume	142,189
Average Volume	80,463
Open	1,311.00
Previous Close	1,311.50
Day's Range	1,297.00 - 1,352.20
52-Week Range	1,302.00 - 2,451.70
Beta	0.58
RSI	33.67
Earnings Date	Feb 12, 2026

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,571
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.